Absci Partners with M2GEN to Accelerate Drug Creation for Oncology
Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments faster Vancouver, Wash. and TAMPA, Fla – (April 04, 2023) – Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomics data to…